Background. Although spread of multi-drug-resistant Gram-negative pathogens causes serious problems, there are limited therapeutic options because of the lack of new promising antibacterial agents. S-649266 ('266) is a novel catechol-substituted siderophore cephalosporin antibiotic with potent antibacterial activity against Gram-negative bacteria including drug-resistant pathogens. This study investigated the mechanisms of enhanced activity and β-lactamase stability of '266.
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Methods. MIC was determined by brothmicrodilution methods by using apotransferrin (apo-T) into the medium and treatment of the medium by Chelex resin.
Chelating activity of '266 and iron was evaluated by Chromeazrol B and uptake of '266 was measured by using calcein fluorescence. The kinetic parameters of '266 against carbapenemases were determined to evaluate the stability.
Results. The in vitro activity of '266 increased under free iron deficient conditions such as apo-T supplemented medium. These culture conditions mimic the condition in human infection. The evaluation with Chromeazrol B showed the strong chelating activity of '266 with ferric iron. The rate of iron uptake by P. aeruginosa cells were enhanced by addition of '266, suggesting that '266 had siderophore activity with iron transported efficiently into P. aeruginosa. The catalytic efficiency (kcat/Km) of '266 against IMP-1, VIM-2, L1 were 5 × 10 3 , 5 × 10 3 , 2 × 10 4 M −1 s −1 , respectively. These values were approximately 10 to 1,000 fold lower than those of meropenem, ceftazidime, and cefepime. The relative hydrolysis velocity of '266 against NDM-1 was lower than that of meropenem. No or only a slight hydrolysis of '266 was observed against KPC-3, P99 and OXA-23, indicating the high stability of '266 to these β-lactamases.
Conclusion. The in vitro activity of S-649266 was enhanced under free iron deficient conditions which mimic the condition in human infection. S-649266, acting through siderophore receptors was transported into P.aeruginosa. S-649266 was more stable against carbapenemase than other cephalosporins and carbapenems. These results showed that '266 is a promising siderophore cephalosporin to treat multi-drug resistant Gram-negative pathogens.
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